Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GE HealthCare Technologies Inc. Market Cap
The GE HealthCare Technologies Inc. (GEHC) share price is expected to increase by 19.36% over the next year. This is based on calculating the average 12-month share price estimate provided by 20 stock analysts who have covered GEHC. Price targets range from $74 at the low end to $110 at the high end. The current analyst consensus for GEHC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
GEHC is a stock in Healthcare which has been forecasted to be worth $96.96632 as an average. On the higher end, the forecast price is $110 USD by David Toung from Argus Research and on the lower end GEHC is forecasted to be $74 by Patrick Wood from Morgan Stanley.
These are the latest 20 analyst ratings of GEHC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Larry Biegelsen Wells Fargo | Overweight | $96 | Maintains | Oct 31, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $102 | Maintains | Oct 1, 2024 |
| Rick Wise Stifel | Buy | $102 | Maintains | Sep 30, 2024 |
| Graham Doyle UBS | Sell | $74 | Downgrade | Sep 26, 2024 |
| Ryan Zimmerman BTIG | Buy | $100 | Upgrade | Sep 18, 2024 |
| Robbie Marcus JP Morgan | Neutral | $90 | Initiates | Sep 9, 2024 |
| Rick Wise Stifel | Buy | $100 | Initiates | Aug 6, 2024 |
| David Roman Goldman Sachs | Neutral | $87 | Initiates | May 30, 2024 |
| Anthony Petrone Mizuho | Buy | $105 | Maintains | May 1, 2024 |
| Craig Bijou B of A Securities | Neutral | $86 | Maintains | May 1, 2024 |
| Anthony Petrone Mizuho | Buy | $110 | Maintains | Apr 11, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $100 | Maintains | Apr 4, 2024 |
| Joanne Wuensch Citigroup | Buy | $103 | Maintains | Apr 3, 2024 |
| David Toung Argus Research | Buy | $110 | Maintains | Apr 1, 2024 |
| Sezgi Oezener HSBC | Buy | $100 | Initiates | Feb 15, 2024 |
| Graham Doyle UBS | Neutral | $88 | Upgrade | Feb 12, 2024 |
| Patrick Wood Morgan Stanley | Equal-Weight | $86 | Maintains | Feb 12, 2024 |
| Anthony Petrone Mizuho | Buy | $96 | Maintains | Feb 7, 2024 |
| Patrick Wood Morgan Stanley | Equal-Weight | $74 | Maintains | Dec 4, 2023 |
| Matthew Taylor Jefferies | Hold | $80 | Initiates | Nov 30, 2023 |
When did it IPO
2023
Staff Count
51,000
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Peter J. Arduini
Market Cap
$38.46B
In 2023, GEHC generated $19.55B in revenue, which was a increase of 6.60% from the previous year. This can be seen as a signal that GEHC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - GE HealthCare's Aurora will broaden CT procedure options, while Clarify DL will improve SPECT image quality, potentially enhancing their product offerings and market position.
Why It Matters - GE HealthCare's advancements in CT procedures and SPECT image quality may boost demand for its products, potentially increasing revenue and improving market position, influencing investor sentiment positively.
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - GE HealthCare launched three advanced deep learning imaging solutions at RSNA 2024, aimed at enhancing operational efficiency in radiology and addressing clinician burnout.
Why It Matters - GE HealthCare's new advanced imaging solutions could enhance operational efficiency and reduce clinician burnout, potentially boosting sales and market share, positively impacting stock performance.
Fri, 06 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - GE HealthCare Technologies is rated a buy, citing strong growth prospects, a healthy backlog, and new innovations like Flyrcado. EBIT margins target high teens to 20% through optimization and pricing strategies.
Why It Matters - GE HealthCare's strong growth prospects, healthy backlog, and innovative products position it well for future profitability, making it an attractive investment compared to peers.
Mon, 02 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - GE HealthCare has launched the Sonic DL for 3D, designed to reduce scan times and enhance image quality for most MR scans, potentially improving operational efficiency in healthcare settings.
Why It Matters - GE HealthCare's Sonic DL technology could enhance operational efficiency and attract more healthcare clients, potentially boosting revenue and market share, impacting stock performance positively.
Wed, 04 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - GE HealthCare has submitted its CleaRecon DL technology to the FDA, aimed at enhancing Cone Beam Computed Tomography (CBCT) imaging.
Why It Matters - The FDA submission for CleaRecon DL signals potential advancements in imaging technology, which could enhance GE HealthCare's competitive edge and revenue growth in the healthcare sector.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - GE HealthCare submitted a 510(k) application to the FDA for CleaRecon DL, an AI-based technology to enhance CBCT imaging quality. Clearance is pending; the technology will be showcased at RSNA 2024.
Why It Matters - GE HealthCare's 510(k) submission for AI-enhanced imaging technology could lead to a competitive edge in the medical imaging market, impacting future revenue and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
